SynthesisEuropean heart journal. Quality of care & clinical outcomes2025
Prevalence, progression, and clinical outcomes of mitral valve prolapse: a systematic review and meta-analysis.
Synthesis in European heart journal. Quality of care & clinical outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Arrhythmic risk in mitral valve prolapse with mitral annular disjunction: meta-analysis of longitudinal studies.Scientific reports · 2025Pooled it
- Circulating Biomarkers Related to Mitral Valve Prolapse: Current Evidence and Mechanistic Perspective.Current cardiology reports · 2026Review
- Mitral Valve Prolapse and Anxiety Disorders: A Systematic Review of Evidence in Both Directions and Meta-Analysis.Journal of clinical medicine · 2026Review
- ZFP36 inhibits the pro-apoptotic effects of transforming growth factor β1 on mitral valve interstitial cells via the GTP-binding protein 6 pathway in mitral valve prolapse.Experimental physiology · 2026Article
- Knowledge mapping and research trends in degenerative mitral regurgitation: a bibliometric analysis from 2004 to 2024.Journal of thoracic disease · 2026Article
- Progression of mitral and tricuspid regurgitation in patients with and without atrial fibrillation.Frontiers in cardiovascular medicine · 2026Article
- Mechanisms of mitral valve development and disease.Frontiers in cardiovascular medicine · 2026Review
- Multimodal diagnostic imaging for early mitral valve disease: integration of current and emerging modalities-a narrative review.Cardiovascular diagnosis and therapy · 2025Review
- Transthoracic and Transesophageal Echocardiography in the Diagnosis and Management of Mitral Regurgitation.Current cardiology reports · 2025Review
- Mitral Annular Disjunction and Arrhythmic Risk: Case Series and State of the Art.Biomedicines · 2025Article
- Joint Hypermobility: An Under-Recognised Cause of Palpitations, Dizziness, and Syncope in Young Females.Journal of clinical medicine · 2025Article
- Management of Arrhythmic Mitral Valve Prolapse: Potential Impact and Current Evidence.Reviews in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe prevalence of mitral valve prolapse (MVP) varies across populations and age groups; its natural history and clinical outcomes remain unclear. This meta-analysis established the prevalence of MVP in the general population, in associated syndromes and at different ages. It also determined the rate of progression and the incidence of adverse outcomes. METHODS AND
resultsA systematic search identified original reports on the prevalence of MVP and related outcomes. A total of 83 studies met inclusion: 47 (n = 992 944) non-syndrome associated; 31 (n = 3067) syndrome associated; and 5 (n = 1287) described mitral regurgitation (MR) progression or adverse outcomes. In the general population, the prevalence was 1.35% but higher in hospital cohorts (8.7%). Age-stratified prevalence was 0.5, 1.8, 2.7, and 2.0% in neonates, children, adolescents and adults, respectively. Meta-regression and subgroup analysis found no significant difference (P = 0.81) across ages but revealed a significantly higher prevalence in older compared to young adults (2.87% vs. 0.67%, P = 0.01). Prevalence rates were markedly higher in patients with genetic syndromes. MR progressed at 5.5 per 100 person-years, overall. Event rates for all-cause mortality, development of heart failure, and need for mitral valve intervention were 1.7, 1.0, and 1.2 per 100 person-years, respectively.
conclusionMVP is common, with greater prevalence in syndromes. Although more common with age, MVP is observed in infants. MVP related MR is progressive, especially in moderate MR, and there is a signal of excess mortality for unclear reasons. Valve services must manage the whole life journey and the potential risks associated with MVP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.